Päivi Galambosi1, Vilho Hiilesmaa2, Veli-Matti Ulander3, Leena Laitinen4, Aila Tiitinen5, Risto Kaaja6. 1. University of Helsinki, Helsinki University Hospital, Department of Obstetrics and Gynaecology, Haartmaninkatu 2, 00290 Helsinki, Finland. Electronic address: paivi.galambosi@gmail.com. 2. University of Helsinki, Helsinki University Hospital, Department of Obstetrics and Gynaecology, Haartmaninkatu 2, 00290 Helsinki, Finland. Electronic address: hiilesmaa@gmail.com. 3. University of Helsinki, Helsinki University Hospital, Department of Obstetrics and Gynaecology, Haartmaninkatu 2, 00290 Helsinki, Finland. Electronic address: veli-matti.ulander@hus.fi. 4. University of Helsinki, Helsinki University Hospital, Department of Obstetrics and Gynaecology, Haartmaninkatu 2, 00290 Helsinki, Finland. Electronic address: leena.laitinen@hus.fi. 5. University of Helsinki, Helsinki University Hospital, Department of Obstetrics and Gynaecology, Haartmaninkatu 2, 00290 Helsinki, Finland. Electronic address: aila.tiitinen@hus.fi. 6. University of Turku and Turku University Central Hospital, Kiinamyllynkatu 4-8, 20520 Turku, Finland. Electronic address: riskaa@utu.fi.
Abstract
INTRODUCTION: In contrast to unfractionated heparin (UFH), use of low-molecular weight heparin (LMWH) during pregnancy has not been reported to be associated with a significant decrease in bone mineral density (BMD). The aim of this study was to investigate whether long-term use of LMWH during pregnancy is associated with subsequent decrease in BMD or with increased number of osteoporotic fractures. MATERIALS AND METHODS: In this observational cohort study BMD was measured by dual energy X-ray absorptiometry (DEXA) 4-7years after the last delivery in 152 women. Ninety-two women had prolonged LMWH-exposure during pregnancy - 75 as prophylaxis and 17 as treatment for venous thromboembolic event (VTE). Dalteparin and enoxaparin were the LMWH-preparations used. Sixty women without LMWH-exposure served as controls. A questionnaire about lifestyle factors and medical history was filled out by the subjects. RESULTS: Lumbar spine BMD in the LMWH users was lower than that in the controls both in the prophylactic group (1.22g/cm(2) vs. 1.27g/cm(2); p=0.03), and in the treatment group (1.20g/cm(2) vs. 1.27g/cm(2); p=0.07). BMD in femoral neck did not differ between the LMWH-users and controls. However, after adjusting for potential confounding factors, LMWH-exposure did not remain associated with decreased BMD in lumbar spine. Use of contraceptive pills was positively associated with BMD in lumbar spine. Incidence of osteopenia was 13% in the LMWH-group and 8% in the control-group, (p=0.4). No osteoporosis or osteoporotic fractures were found. CONCLUSIONS: Prolonged use of LMWH during pregnancy was not associated with subsequent decrease in BMD, osteopenia, osteoporosis, or osteoporotic fractures.
INTRODUCTION: In contrast to unfractionated heparin (UFH), use of low-molecular weight heparin (LMWH) during pregnancy has not been reported to be associated with a significant decrease in bone mineral density (BMD). The aim of this study was to investigate whether long-term use of LMWH during pregnancy is associated with subsequent decrease in BMD or with increased number of osteoporotic fractures. MATERIALS AND METHODS: In this observational cohort study BMD was measured by dual energy X-ray absorptiometry (DEXA) 4-7years after the last delivery in 152 women. Ninety-two women had prolonged LMWH-exposure during pregnancy - 75 as prophylaxis and 17 as treatment for venous thromboembolic event (VTE). Dalteparin and enoxaparin were the LMWH-preparations used. Sixty women without LMWH-exposure served as controls. A questionnaire about lifestyle factors and medical history was filled out by the subjects. RESULTS: Lumbar spine BMD in the LMWH users was lower than that in the controls both in the prophylactic group (1.22g/cm(2) vs. 1.27g/cm(2); p=0.03), and in the treatment group (1.20g/cm(2) vs. 1.27g/cm(2); p=0.07). BMD in femoral neck did not differ between the LMWH-users and controls. However, after adjusting for potential confounding factors, LMWH-exposure did not remain associated with decreased BMD in lumbar spine. Use of contraceptive pills was positively associated with BMD in lumbar spine. Incidence of osteopenia was 13% in the LMWH-group and 8% in the control-group, (p=0.4). No osteoporosis or osteoporotic fractures were found. CONCLUSIONS: Prolonged use of LMWH during pregnancy was not associated with subsequent decrease in BMD, osteopenia, osteoporosis, or osteoporotic fractures.
Authors: Abraham Yair Lujano-Negrete; Martha Cecilia Rodríguez-Ruiz; Cassandra Michele Skinner-Taylor; Lorena Perez-Barbosa; Jesus Alberto Cardenas de la Garza; Pedro Alberto García-Hernández; Luis Gerardo Espinosa-Banuelos; Luz Fernanda Gutierrez-Leal; Sofia Jezzini-Martínez; Dionicio Ángel Galarza-Delgado Journal: Arch Osteoporos Date: 2022-02-19 Impact factor: 2.617
Authors: Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg Journal: Blood Adv Date: 2018-11-27
Authors: L S Litvinova; K A Yurova; O G Khaziakhmatova; M Yu Khlusova; V V Malashchenko; E O Shunkin; N M Todosenko; I K Norkin; P A Ivanov; I A Khlusov Journal: Biochem Mosc Suppl B Biomed Chem Date: 2021-05-14